Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Sesen, Julie ^a   Dahan, Perrine ^a   Scotland, Sarah J ^a,b   Saland, Estelle ^a   Dang, Van Thi ^a   Lemarié, Anthony ^a   Tyler, Betty M ^b   Brem, Henry ^b   Toulas, Christine ^a   Moyal, Elizabeth Cohen Jonathan ^a   Sarry, Jean Emmanuel ^a   Skuli, Nicolas ^a  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; TEMOZOLOMIDE; ADENYLATE KINASE; DACARBAZINE; DDIT4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVATION; GENE SILENCING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IRRADIATION; MOUSE; NONHUMAN; NUDE MOUSE; OXYGEN CONSUMPTION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CELL DIVISION; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GLYCOLYSIS; METABOLISM; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

MUS MUSCULUS;

ADENYLATE KINASE; ANIMALS; APOPTOSIS; AUTOPHAGY; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DACARBAZINE; DRUG SYNERGISM; GLIOBLASTOMA; GLYCOLYSIS; HUMANS; METFORMIN; MICE; MICE, NUDE; MITOCHONDRIA; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928902734     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123721     Document Type: Article

References (61)

1. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013 Jan; 10(1):14-26. doi: 10.1038/nrclinonc.2012.204 PMID: 23183634
2. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014; 9:1-25. doi: 10.1146/annurev-pathol-011110-130324 PMID: 23937436
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10; 352(10):987-96. PMID: 15758009
4. Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol. 2009 Oct; 6(10):596-603. doi: 10.1038/nrclinonc.2009.128 PMID: 19707193
5. Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013 May 28; 332(2):237-48. doi: 10.1016/j.canlet.2012.01.007 PMID: 22261329
6. Wick W, Platten M. Understanding and targeting alkylator resistance in glioblastoma. Cancer Discov. 2014 Oct; 4(10):1120-2. doi: 10.1158/2159-8290.CD-14-0918 PMID: 25274683
7. Zhang WB, Wang Z, Shu F, Jin YH, Liu HY, Wang QJ, et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem. 2010 Dec 24; 285(52):40461-71. doi: 10.1074/jbc.M110.164046 PMID: 20880848
8. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008 Jun; 13(6):472-82. doi: 10.1016/j.ccr.2008.05.005 PMID: 18538731
9. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011 Sep; 10(9):671-84. doi: 10.1038/nrd3504 PMID: 21878982
10. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002 Jul 2; 137(1):25-33. PMID: 12093242
11. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2011 May 5; 11(5):390-401.
12. Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood. 2010 Nov 18; 116(20):4262-73. doi: 10.1182/blood-2010-02-269837 PMID: 20668229
13. Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M, et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia. 2012 Jan; 26(1):91-100. doi: 10.1038/leu.2011.269 PMID: 21968881
14. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012 Sep; 2(9):778-90. doi: 10.1158/2159-8290.CD-12-0263 PMID: 22926251
15. Pollak M. Potential applications for biguanides in oncology. J Clin Invest. 2013 Sep 3; 123(9):3693-700. doi: 10.1172/JCI67232 PMID: 23999444
16. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007 May; 64(10):1290-302. PMID: 17447005
17. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009 Aug 15; 69(16):6539-45. doi: 10.1158/0008-5472.CAN-09-0418 PMID: 19679549
18. Sato A, Sunayama J, Okada M, Watanabe E, Seino S, Shibuya K, et al. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med. 2012 Nov; 1(11):811-24. doi: 10.5966/sctm.2012-0058 PMID: 23197693
19. Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S, Chow LM, et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E435-44. doi: 10.1073/pnas.1311121111 PMID: 24474794
20. Sesen J, Cammas A, Scotland SJ, Elefterion B, Lemarie A, Millevoi S, et al. Int6/eIF3e is essential for proliferation and survival of human glioblastoma cells. Int J Mol Sci. 2014; 15(2):2172-90. doi: 10.3390/ijms15022172 PMID: 24481065
21. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 2007 Jan; 292(1):C125-36. PMID: 16971499
22. Scotland S, Saland E, Skuli N, de Toni F, Boutzen H, Micklow E, et al. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia. 2013 Nov; 27(11):2129-38. doi: 10.1038/leu.2013.107 PMID: 23568147
23. Lemarie A, Grimm S. Mutations in the heme b-binding residue of SDHC inhibit assembly of respiratory chain complex II in mammalian cells. Mitochondrion. 2009 Jul; 9(4):254-60. doi: 10.1016/j.mito.2009.03.004 PMID: 19332149
24. Janssen AJ, Trijbels FJ, Sengers RC, Smeitink JA, van den Heuvel LP, Wintjes LT, et al. Spectrophotometric assay for complex I of the respiratory chain in tissue samples and cultured fibroblasts. Clin Chem. 2007 Apr; 53(4):729-34. PMID: 17332151
25. Ucbek A, Ozunal ZG, Uzun O, Gepdiremen A. Effect of metformin on the human T98G glioblastoma multiforme cell line. Exp Ther Med. 2014 May; 7(5):1285-90. PMID: 24940426
26. Najbauer J, Kraljik N, Nemeth P. Glioma Stem Cells: Markers, Hallmarks and Therapeutic Targeting by Metformin. Pathol Oncol Res. 2014 Aug 29.
27. Icard P, Lincet H. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim Biophys Acta. 2012 Dec; 1826(2):423-33. doi: 10.1016/j.bbcan.2012.07.001 PMID: 22841746
28. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2011; 2:e199. doi: 10.1038/cddis.2011.86 PMID: 21881601
29. Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, et al. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol. 2010 Jan 25; 651(1-3):41-50. doi: 10.1016/j.ejphar.2010.11.012 PMID: 21126518
30. Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, et al. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014; 5: e1088. doi: 10.1038/cddis.2014.59 PMID: 24577086
31. Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 2012; 3:e275. doi: 10.1038/cddis.2012.13 PMID: 22378068
32. Wurth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A, Parodi A, et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle. 2013 Jan 1; 12(1):145-56. doi: 10.4161/cc.23050 PMID: 23255107
33. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008 Jan 15; 22(2):239-51. doi: 10.1101/gad.1617608 PMID: 18198340
34. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N, et al. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol. 2011 Oct 15; 668(3):373-82. doi: 10.1016/j.ejphar.2011.07.004 PMID: 21806981
35. Kisfalvi K, Moro A, Sinnett-Smith J, Eibl G, Rozengurt E. Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas. 2013 Jul; 42(5):781-5. doi: 10.1097/MPA.0b013e31827aec40 PMID: 23462329
36. Aldea M, Tomuleasa C, Petrushev B, Susman S, Kacso GI, Irimie A, et al. Antidiabetic pharmacology: a link between metabolic syndrome and neuro-oncology? J BUON. 2011 Jul-Sep; 16(3):409-13. PMID: 22006741
37. Kast RE, Karpel-Massler G, Halatsch ME. Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin? Br J Pharmacol. 2011 Nov; 164(5):1393-6. doi: 10.1111/j.1476-5381.2011.01320.x PMID: 21410456
38. Carmignani M, Volpe AR, Aldea M, Soritau O, Irimie A, Florian IS, et al. Glioblastoma stem cells: a new target for metformin and arsenic trioxide. J Biol Regul Homeost Agents. 2014 Jan-Mar; 28(1):1-15. PMID: 24750786
39. Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep. 2010 Sep-Oct; 62(5):956-65. PMID: 21098880
40. Valle G, Carmignani M, Brunetti L, Volpe AR. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. J BUON. 2011 Oct-Dec; 16(4):787; author reply -8. PMID: 22331745
41. Gao LB, Tian S, Gao HH, Xu YY. Metformin inhibits glioma cell U251 invasion by downregulation of fibulin-3. Neuroreport. 2013 Jul 10; 24(10):504-8. doi: 10.1097/WNR.0b013e32836277fb PMID: 23660683
42. Ben Sahra I, Tanti JF, Bost F. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy. 2010 Jul; 6(5):670-1. PMID: 20559023
43. Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010 Aug; 123(1):271-9. doi: 10.1007/s10549-010-0763-9 PMID: 20135346
44. Wurth R, Barbieri F, Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int. 2014; 2014:126586. doi: 10.1155/2014/126586 PMID: 24527434
45. Eisenberg-Lerner A, Kimchi A. The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis. 2009 Apr; 14(4):376-91. doi: 10.1007/s10495-008-0307-5 PMID: 19172397
46. Zhang Y, Guan M, Zheng Z, Zhang Q, Gao F, Xue Y. Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS One. 2013; 8(11):e81264. doi: 10.1371/journal.pone.0081264 PMID: 24278407
47. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014 Jun 26; 510(7506):542-6. doi: 10.1038/nature13270 PMID: 24847880
48. Pajonk F, Vlashi E. Characterization of the stem cell niche and its importance in radiobiological response. Semin Radiat Oncol. 2013 Oct; 23(4):237-41. doi: 10.1016/j.semradonc.2013.05.007 PMID: 24012337
49. Vucicevic L, Misirkic M, Janjetovic K, Harhaji-Trajkovic L, Prica M, Stevanovic D, et al. AMP-activated protein kinase-dependent and-independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 2009 Jun 1; 77(11):1684-93. doi: 10.1016/j.bcp.2009.03.005 PMID: 19428322
50. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011 Jul 1; 71(13):4366-72. doi: 10.1158/0008-5472.CAN-10-1769 PMID: 21540236
51. Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol. 2005 Jul; 25(14):5834-45. PMID: 15988001
52. Reiling JH, Hafen E. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 2004 Dec 1; 18(23):2879-92. PMID: 15545626
53. Jin HO, An S, Lee HC, Woo SH, Seo SK, Choe TB, et al. Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. Cell Signal. 2007 Jul; 19(7):1393-403. PMID: 17307335
54. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol. 2002 Apr; 22(7):2283-93. PMID: 11884613
55. Vadysirisack DD, Baenke F, Ory B, Lei K, Ellisen LW. Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol. 2011 Nov; 31(21):4356-65. doi: 10.1128/MCB.05541-11 PMID: 21896779
56. Horak P, Crawford AR, Vadysirisack DD, Nash ZM, DeYoung MP, Sgroi D, et al. Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci U S A. 2010 Mar 9; 107(10):4675-80. doi: 10.1073/pnas.0907705107 PMID: 20176937
57. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008 Sep; 5(3):157-67. doi: 10.3132/dvdr.2008.027 PMID: 18777488
58. Fasih A, Elbaz HA, Huttemann M, Konski AA, Zielske SP. Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. Radiat Res. 2014 Jul; 182(1):50-9. doi: 10.1667/RR13568.1 PMID: 24909911
59. Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 2013 May 28; 108(10):2021-32. doi: 10.1038/bjc.2013.187 PMID: 23632475
60. Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012; 2:362. doi: 10.1038/srep00362 PMID: 22500211
61. Aldea MD, Petrushev B, Soritau O, Tomuleasa CI, Berindan-Neagoe I, Filip AG, et al. Metformin plus sorafenib highly impacts temozolomideresistant glioblastoma stem-like cells. J BUON. 2014 Apr-Jun; 19(2):502-11. PMID: 24965413